Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 May 2017Website:
http://www.ovidrx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:42:09 GMTDividend
Analysts recommendations
Institutional Ownership
OVID Latest News
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology company focused on developing Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitors and other innovative therapeutic compounds, today announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888/GV101 capsule. Ovid and Graviton plan to progress to a Phase 2 clinical study in cerebral cavernous malformations (CCM) later this year.
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/ovid-therapeutics-inc-lawsuit-submission-form?prid=88392&wire=1 or contact Joseph E.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/ovid-therapeutics-inc-lawsuit-submission-form?prid=87695&wire=1 or contact Joseph E.
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, reports that Takeda Pharmaceutical Company Limited (Takeda) has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Ovid Therapeutics (OVID) reported a quarterly loss of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.23. This is an improvement from the loss of $0.19 per share reported a year ago.
What type of business is Ovid Therapeutics?
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
What sector is Ovid Therapeutics in?
Ovid Therapeutics is in the Healthcare sector
What industry is Ovid Therapeutics in?
Ovid Therapeutics is in the Biotechnology industry
What country is Ovid Therapeutics from?
Ovid Therapeutics is headquartered in United States
When did Ovid Therapeutics go public?
Ovid Therapeutics initial public offering (IPO) was on 05 May 2017
What is Ovid Therapeutics website?
https://www.ovidrx.com
Is Ovid Therapeutics in the S&P 500?
No, Ovid Therapeutics is not included in the S&P 500 index
Is Ovid Therapeutics in the NASDAQ 100?
No, Ovid Therapeutics is not included in the NASDAQ 100 index
Is Ovid Therapeutics in the Dow Jones?
No, Ovid Therapeutics is not included in the Dow Jones index
When does Ovid Therapeutics report earnings?
The next expected earnings date for Ovid Therapeutics is 02 August 2024